Latest Breaking News On - Xeri board - Page 1 : comparemela.com

Published: Dec 31, 2020     CHICAGO (BUSINESS WIRE) Xeris Pharmaceuticals, Inc., Inc. (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on December 30, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 38,250 shares, and restricted stock units for an aggregate of 35,100 shares, of its common stock to 7 new employee(s) under Xeris’ Inducement Equity Plan. Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual s entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The non-qualified stock options will vest over a period of four years, e

United statesXeris pharmaceuticals incCompensation committee of xeri board directorsCompensation committeeXeri boardXeri inducement equityInducement equity planXeri inducement equity planXeris pharmaceuticalsXeris pharmaceuticals announced inducement grants under nasdaq listing rule 5635c 4ஒன்றுபட்டது மாநிலங்களில்இழப்பீடு குழு